UCB is entering a next stage of growth as it turns the page on the loss of exclusivity of several of its mature assets. The new chapter will focus strongly on five growth drivers: Bimzelx, Rystiggo, Zilbrysq, Fintepla and Evenity. Jointly, these assets could deliver significant topline growth and margin improvements in the coming years. We have conducted an extensive update of our model to incorporate these new dynamics. Our DCF-based valuation points to a fair value of € 143 per share (previous...
D'Ieteren's engine keeps on running, with the adj. PBT (gs) up 28.1% in 2023, driven by a strong performance at Belron, Auto, and the full consolidation of PHE. Going forward, we expect the adj. PBT (gs) to grow 9% in 2024, and to accelerate to +15.7% in 2025 driven by the completion of the transformation programme at Belron. With D'Ieteren trading at only 13.9x the adj. fwd P/E, we believe investors are not giving D'Ieteren enough credit for its excellent track record and growth prospects. In a...
Our Bimzelx launch tracker tool keeps an eye on the ongoing commercialization of Bimzelx in the US by looking at total prescriptions (TRx). Our latest figure for week 22 points to 898 TRx, down 2% versus last week's result, and up 11% on a 4-week rolling basis. Altogether, we see a smooth ramp-up for Bimzelx in its first months since launch.
>Underperform, price target to €19 (was €25.5) - We change our rating to Underperform (was Neutral) and lower our TP to €19 per share (relative valuation outcome €17.5, weight 40% and DCF, outcome €20, weight 60%). Our investment thesis remains unchanged with declining volumes and thus sales and margins for Recycling and Catalysis in the medium and long term and lower than projected revenues and margins (and thus returns) for Battery Materials. Due to the material c...
We updated our Materialise model after 1Q24 revenues decreased 3% y/y as 1Q23 was an exceptionally strong quarter showing 24% growth. In 1Q24, Materialise's Medical segment continued to lead the way with 8% y/y revenue growth, while revenue declined in its Manufacturing and Software segments amidst less favourable market conditions. While continued investments in sustainable growth and the ongoing conversion to a recurring revenue business model impacted Materialise's operational profitability,...
>Reiterating 2024 EBITDA guidance of €900-€950m - Umicore has published a 1 page qualitative trading update about Q1 2024 in which it reiterated EBITDA guidance for 2024 (€900-€950m) so in that sense there are little surprises. Consensus is at €932m and we are at €909m. No analyst call is planned.Catalysis and Recycling performing in line with expectations - Umicore states that Catalysis is making headway on costs and efficiency gains (also in WC) whi...
Basic-Fit: 1Q24 update in line, FY24 outlook in line with consensus at mid-point. bpost: Agreement on Flemish newspaper delivery; risk of provisions largely removed. Cofinimmo: Q1 results in line. Corbion: Tail wags the dog. IMCD: The last hurdle was a harsh clip. Proximus: Strong start to the year, guidance unchanged ahead of Digi arrival. Recticel: Kingspan 1Q24 trading update. Signify: 1Q24 results; revenue decline accelerates. Umicore: Confirms FY 2024 EBITDA guidance range. ...
Umicore commented that market dynamics in 1Q were in line with its expectations and the company reiterated its FY24 adj EBITDA guidance range of € 900-950m which represents at midpoint a 5% drop y/y. We continue to believe Umicore is well placed to play an important role in the electrification of transportation as we believe that global OEMs are still determined to establish local supply chains in Europe and North America. HLM and solid-state technologies will in our opinion support the position...
• In its qualitative Q1-24 trading update Umicore indicated that so far market dynamics are in line with its expectations. It confirms its FY24 EBITDA guidance range of EUR 900-950m.• We stick to our view that the doubts on battery materials are unlikely to be removed soon and that 2024 will be another transition year.• We stick to Hold and TP of EUR 23 based on our SOTP with an overall target EV/EBITDA of around 8x.
Azelis: Strong margin performance in weak trading results in 3% EBITA beat. BE Semiconductor Industries: 1Q24 results; prolonged downcycle. Coca-Cola Europacific Partners plc: Messy but good. DWS: Record breaking. Flow Traders: Crypto Kings. Fugro: Here we go again. Kinepolis: Weak start to the year, but a bit better than feared. UCB: Changes in the group executive committee. Unilever: Heading in the right direction. Vonovia: Disposal of 4,500 apartments for €700m. Wolters Kl...
Despite the weaker 1Q24 film offering and the lower visitor numbers associated with this (7.3m in 1Q24 -perfect in line with our estimates- versus 8.1m in 1Q23), we applauded that Kinepolis indicated they generated strong results per visitor and 1Q24 FCF was even stronger than in 1Q23. Kinepolis highlighted that this ‘Sales/visitor' remained high, thanks to strong demand for premium products, but was occasionally impacted by the product mix in 1Q. We maintain our € 53 Target Price and Buy.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.